Loading...
•
Dec 31, 2020
Aytu BioScience Q2 2021 Earnings Report
Reported record fiscal Q2 2021 net revenue with increased consumer health revenue.
Key Takeaways
Aytu BioScience reported a record fiscal Q2 2021 net revenue of $15.1 million, a 377% increase year-over-year. The Consumer Health revenue reached an all-time high of $7.9 million, and the company ended the quarter with $62.3 million in cash, cash equivalents, and restricted cash.
Net revenue reached an all-time high of $15.1 million, compared to $3.2 million for Q2 2020.
Consumer Health division net revenue was an all-time high of $7.9 million.
Rx division net revenue was $7.2 million.
Ended the quarter with $62.3 million in cash, cash equivalents and restricted cash.
Aytu BioScience
Aytu BioScience
Forward Guidance
The merger accelerates the company’s transformation, and, upon closing, we expect to begin realizing estimated annualized cost synergies of $15 million in FY 2022.
Positive Outlook
- Expected synergies of $15 million in FY 2022.
- Adds Neos' established, multi-brand ADHD portfolio.
- Enhances footprint in pediatrics.
- Expands Aytu’s presence in adjacent specialty care segments.
- Creates the opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program.